



HAL
open science

Ubiquitin, SUMO, and NEDD8: Key Targets of Bacterial Pathogens

David Ribet, Pascale Cossart

► **To cite this version:**

David Ribet, Pascale Cossart. Ubiquitin, SUMO, and NEDD8: Key Targets of Bacterial Pathogens. Trends in Cell Biology, In press, 10.1016/j.tcb.2018.07.005 . pasteur-01890548v1

HAL Id: pasteur-01890548

<https://pasteur.hal.science/pasteur-01890548v1>

Submitted on 10 Oct 2018 (v1), last revised 10 Oct 2018 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Ubiquitin, SUMO and Nedd8 ; Critical Targets of Bacterial Pathogens**

2

3

4 David Ribet^{1,*} and Pascale Cossart^{2,*}

5

6 1. Normandie Université, Université de Rouen, Institute for Research and Innovation in
7 Biomedicine, INSERM, UMR1073, Nutrition Inflammation and Dysfunction of the gut-brain
8 axis, Rouen, France.

9 2. Institut Pasteur, INSERM, INRA, Unité des Interactions Bactéries-Cellules, Paris, France.

10

11 * Correspondence : pascale.cossart@pasteur.fr and david.ribet@inserm.fr

12

13 **Keywords** : Ubiquitin, SUMO, ISG15, NEDD8, host-pathogen interactions

14 **Abstract**

15

16 Manipulation of host protein post-translational modifications is used by various pathogens to
17 interfere with host cell functions. Among these modifications, ubiquitin and ubiquitin-like
18 proteins constitute critical targets as they are regulators of pathways essential for the host cell.
19 In particular, these post-translational modifiers control pathways that have been described as
20 critical for infection such as pathogen entry, replication, propagation or detection by the host.
21 Although bacterial pathogens lack ubiquitin or ubiquitin-like protein systems, many of them
22 produce proteins that specifically interfere with these host post-translational modifications
23 during infection. In this review, we will discuss the different mechanisms used by bacteria to
24 interfere with host ubiquitin and the two ubiquitin-like proteins (UBLs) SUMO and NEDD8.

25 **Highlights :**

26

27 * Ubiquitin and UBLs regulate essential pathways of the host cell involved in critical steps of
28 bacterial infections. Not surprisingly, bacterial pathogens have evolved multiple strategies to
29 interfere with these host post-translational modifications.

30

31 * Besides Ubiquitin, UBLs such as SUMO and NEDD8 have recently emerged as prominent
32 targets of bacterial pathogens.

33

34 * Strategies used by bacteria to interfere with host Ubi/UBL encompass the targeting of
35 Ubi/UBL conjugation machineries, the modulation of the Ubi/UBL conjugation level of
36 specific host factors and the direct targeting of Ubi/UBL proteins.

37

38 * Host proteins modified by Ubi/UBL and targeted by bacteria cluster into specific host cell
39 functions such as gene regulation, cytoskeleton dynamics and cell-autonomous immunity.

40

41 * Bacteria hijack the host Ubi/UBL systems to modify their own proteins allowing a regulation
42 of their intracellular localization, stability or interaction abilities.

43

44 **Outstanding questions :**

45

46 * Are the recently described non-canonical ubiquitination mechanisms (*i.e.* conjugation
47 involving non-RING/non-HECT E3 ligases or E1/E2-independent ubiquitin conjugation)
48 strictly restricted to bacteria? Or are there functional homologs of these bacterial enzymes
49 encoded by human cells?

50

51 * Recent improvements in proteomic analyses now allow to thoroughly monitor changes in the
52 host ubiquitinome/"UBL-ome" in response to infection. These approaches usually provide
53 thousands of putative candidate proteins showing altered Ubi/UBL-conjugation level in
54 response to infection. Which strategies researchers should use to cope with this complex set of
55 data and identify the key players affecting the outcome of infection ?

56

57 * What are the mutations in the human population affecting the Ubi/UBL systems that may
58 confer higher susceptibility to bacterial pathogens ?

59

60 * Would drugs targeting bacteria-specific enzymes that interfere with host Ubi/UBL
61 conjugation be efficient to treat infectious diseases ?

62

63 **Ubiquitin and Ubiquitin-like proteins constitute essential modifiers of host proteins**

64

65 Post-translational modification (PTM) of proteins are involved in the regulation of protein
66 stability, activity, localization or interactions with other cellular components. PTMs
67 encompasses a wide range of chemical processes. They include the cleavage of peptide bonds
68 (proteolysis), the modification of specific amino acid side chains such as deamidation (*i.e.* the
69 removal of an NH₃ group) or eliminylation (*i.e.* the irreversible removal of a phosphate group),
70 and the covalent addition of chemical moieties ranging from simple groups (such as phosphate,
71 acetyl or methyl groups) to more complex groups such as sugar, lipids or even small
72 polypeptides [1,2].

73 The human genome encodes several polypeptides that can be covalently linked, via their C-
74 terminal glycine residues, to target proteins. The best-studied of these polypeptides is ubiquitin
75 (Ubi), a small polypeptide of 76 amino acids discovered more than 40 years ago [3-5]. Besides
76 Ubiquitin, other polypeptides such as SUMO (Small Ubiquitin-like Modifier) [6], NEDD8
77 (neural precursor cell expressed developmentally downregulated protein 8) [7], ISG15
78 (interferon-stimulated gene 15) [8] or FAT10 (HLA-F-adjacent transcript 10) [9] can be
79 similarly conjugated to target proteins. These polypeptides are grouped in the so-called
80 ubiquitin-like protein (UBL) family and share high structural homology with ubiquitin [10].

81 The consequences of Ubi/UBL conjugation on the fate of the modified proteins are very diverse.
82 Ubi/UBL can alter the half-life of the modified proteins, for example by targeting them to
83 proteasomal degradation. They can change the targets' structure, thereby affecting their
84 catalytic activity. They can add new surfaces of interactions or mask internal binding domains
85 and change the targets' interactome. In particular, the cell encodes many "receptors" containing
86 Ubiquitin-binding domains (UBDs) or UBL binding domains (such as the SUMO interacting
87 motifs [SIMs]), that interact with proteins once conjugated to Ubi/UBL and "decode" these

88 modifications into biochemical cascades in the cell [6,11]. Besides the well-known example of
89 K48-Ubiquitin chain conjugation (see below), that addresses modified proteins to proteasomal
90 degradation, it is usually difficult to anticipate the consequences of Ubiquitin or UBL
91 conjugation to a given protein.

92 Ubi/UBL are essential regulators of fundamental pathways in cell biology. Some of these
93 pathways are critical for the outcome of infection by pathogens. For example, Ubiquitin is a
94 major regulator of the NF- κ B pathway, that triggers the expression of proinflammatory
95 cytokines in response to pathogen detection [12]. SUMO is a central player in the regulation of
96 type I interferon and in anti-viral gene expression programs [13]. ISG15 plays several
97 independent roles in anti-viral defense and can restrict intracellular bacteria replication *in vitro*
98 and *in vivo* [8,14,15]. FAT10 has been reported to be involved in xenophagy and in
99 antimicrobial defense [9,16]. It is thus not surprising that pathogens have evolved strategies to
100 target Ubi/UBL and interfere with these different cellular processes.

101 In this review, we will present how pathogens interfere with the host Ubi/UBL systems.
102 Ubiquitin and UBL systems have been shown to be targeted by diverse pathogens such as
103 viruses, bacteria or parasites, including *Plasmodium falciparum* or *Toxoplasma gondii* [17-24].
104 We will focus on pathogenic bacteria as they display the widest variety of Ubi/UBL interfering
105 strategies known to date. Although bacteria do not have their own Ubi/UBL systems, numerous
106 species encode virulence factors that actually manipulate host Ubi/UBL systems (Table 1).
107 These factors can be toxins, secreted into the extracellular space in the vicinity of the host cell,
108 or effectors delivered directly into host cells via specialized secretion systems such as Type III
109 secretion systems (T3SS) [25,26]. We discuss how bacterial pathogens (i) target Ubi/UBLs
110 conjugation machineries, (ii) increase or decrease the Ubi/UBL conjugation on specific host
111 factors, (iii) directly target Ubi/UBL polypeptides, or (iv) use host Ubi/UBL to modify their
112 own proteins. We bring to light how these mechanisms allow bacterial pathogens to manipulate

113 specific host cellular pathways in order to promote infection. Understanding how pathogens
114 manipulate host Ubi/UBL pathways is essential as it represents a prominent facet of host-
115 pathogen interactions and may lead to the identification of new therapeutic targets.

116

117 **Ubiquitin/UBL conjugation mechanisms in eukaryotes**

118 Ubiquitination, *i.e.* the conjugation of ubiquitin, usually occurs on lysine residues of target
119 proteins although conjugation to other amino acids such as threonine, serine, or cysteine may
120 also occur [5]. Ubiquitin itself contains seven lysines (K6, K11, K27, K29, K33, K48 and K63)
121 that can serve as sites for additional cycles of ubiquitin attachment, resulting in the formation
122 of ubiquitin chains. The topology of these chains is diverse, ranging from “homotypic” K48-
123 or K63-linked chains, composed of only one type of ubiquitin linkage, to “mixed” chains
124 containing for example both K11 and K63 linkages [4,27]. An additional type of chain, called
125 a “linear” chain, is generated when ubiquitin is attached to the N-terminus of a second ubiquitin
126 [28]. Targeting of a given protein by ubiquitin may thus result in mono-ubiquitination, multi-
127 mono-ubiquitination (*i.e.* several mono-ubiquitinations on different amino acids) or poly-
128 ubiquitination. Ubiquitin is attached to substrates by a three-step enzymatic cascade involving
129 E1 (Ubiquitin activating enzyme), E2 (Ubiquitin-conjugating enzyme) and E3 (Ubiquitin
130 ligase) enzymes [4]. Ubiquitin is generally first activated in an ATP-dependent manner by E1,
131 which links the C-terminal glycine residue of Ubiquitin via a thioester bond to a cysteine residue
132 within the E1 active site. This activated Ubiquitin is then transferred to the catalytic cysteine
133 residue of an E2 enzyme. E3 ligases then finally mediate the transfer of ubiquitin from the E2
134 enzyme to specific substrates. There are two major classes of E3s: the HECT (homologous to
135 the E6-AP carboxyl terminus) type and the RING (really interesting new genes)/U-box type.
136 HECT-type E3 Ubiquitin ligases form a reactive intermediate with ubiquitin before its transfer
137 to the substrate protein whereas RING/U-box-type E3 ligases mediate transfer of ubiquitin from

138 the E2 directly to the substrate protein, without formation of an E3-ubiquitin intermediate [29].
139 Of note, U-box protein E3 ligases display unique preferences for E2 and ubiquitin chain
140 formation compared to RING E3 ligases and may be classified as an independent type of E3
141 [30]. In addition to HECT and RING/U-box E3 ligases, other classes of host E3 ligases have
142 been described such as RBR (RING-between-RING) and RCR (RING-Cys-relay) ligases
143 [31,32]. RBR ligases, such as Parkin and HOIP, combine mechanistic features of RING and
144 HECT-type E3 ligases [31], whereas RCR exhibits esterification activity and intrinsic
145 selectivity for non lysine residues [32]. Conjugation of ubiquitin is a reversible process as
146 several cellular isopeptidases (called deubiquitinases or DUBs) can cleave the covalent bond
147 between ubiquitin and its targets and thereby remove ubiquitin [33].
148 The mechanisms of UBL conjugation on target substrates is similar to that observed for
149 ubiquitination. The enzymes required for all these modifications (*i.e.* E1 UBL activating
150 enzymes, E2 UBL conjugating enzymes and E3 UBL ligases) share highly conserved domain
151 structures [10]. Of note, the number of UBL specific E1, E2 and E3 enzymes is usually smaller
152 than for ubiquitin. For example, SUMO conjugation to thousands of cellular targets seems to
153 rely only on one single SUMO E1 enzyme (SAE1/UBA2), one single SUMO E2 enzyme
154 (UBC9) and a dozen SUMO E3 ligases [6]. Similar to ubiquitin, the formation of UBL chains
155 (where UBLs are conjugated to internal lysines of other UBLs) has been reported for SUMO
156 and NEDD8 [6,7]. Finally, as for Ubiquitin, the host cell encodes several ULPs (UBL-specific
157 proteases) that guarantee the reversibility of UBLs conjugation [6-9].

158

159 **Harnessing of host Ubiquitin and UBL conjugation by bacterial pathogens**

160 *Targeting of host Ubiquitin and UBL conjugation machinery enzymes*

161 Targeting of host E1, E2 or E3 ubiquitin enzymes constitutes a first strategy used by pathogens
162 to dampen ubiquitination (Fig. 1, Key figure). This strategy is used for example by *Shigella*

163 *flexneri*, the etiological agent of bacillary dysentery. This bacterium secretes through its T3SS,
164 an effector, named OspI, that deamidates the glutamine residue at position 100 in the human
165 E2 ubiquitin enzyme UBC13 [34]. This deamidation inactivates UBC13 ubiquitin-conjugating
166 activity, leading to the dampening of the ubiquitin-dependent TRAF6-mediated signaling
167 pathway, which is involved in the activation of the NF- κ B pathway (see below). This finally
168 results in the inhibition of host inflammatory responses during infection [34]. Extracellular
169 pathogens such as enteropathogenic *Escherichia coli* (EPEC) also target the host ubiquitin
170 conjugation machinery. Adhesion of these bacteria to human cells leads to the degradation of
171 UBE1 and UBA6, the two E1 ubiquitin enzymes [35]. This degradation involves aspartyl
172 protease-dependent and proteasome-independent mechanisms and triggers a global decrease of
173 host protein ubiquitination [35].

174 The SUMO conjugation machinery constitutes another target for bacterial pathogens.
175 *Listeria monocytogenes*, the bacterium responsible for human listeriosis, dampens
176 SUMOylation of specific host factors by triggering the degradation of UBC9, the unique host
177 E2 SUMO enzyme [25,36,37]. The degradation of UBC9 is triggered by the formation of pores
178 in the host plasma membrane by the bacterial toxin Listeriolysin O (LLO) [25]. As LLO pores
179 are not reported to affect the activity of host deSUMOylases, UBC9 degradation ultimately
180 results in a shift in the SUMOylation/deSUMOylation equilibrium in the cell and the
181 deSUMOylation of host proteins [25]. The deSUMOylation events triggered by LLO were
182 shown to promote *Listeria* infection. Indeed, removal of SUMO from host factors critical for
183 infection, such as specific transcription factors, may modulate their activity and favor bacterial
184 replication or survival in host cells [25,36]. Of note, other toxins of the same family as LLO,
185 and secreted by extracellular pathogens, were shown to downregulate UBC9, indicating that
186 interference with host SUMOylation is a strategy conserved between different classes of
187 pathogenic bacteria [25]. Inhibition of the SUMOylation machinery has also been observed

188 during infection with *Salmonella* Typhimurium, a bacterium responsible for gastroenteritis in
189 humans, and with *Shigella flexneri* but the underlying mechanisms involved here do not rely
190 on the production of bacterial toxins. In the case of *Salmonella* Typhimurium, infection leads
191 to upregulation in the host cell of two small noncoding RNAs (miR30c and miR30e) that
192 downregulate the UBC9 levels [38]. In the case of *Shigella flexneri*, infection is associated with
193 an influx of calcium into the host cell. This ion flux activates the host proteases calpains, which
194 cleave UBA2, one of the two components of the E1 SUMO enzyme [39]. The resulting
195 inhibition of SUMOylation is associated with an increase in *Shigella* entry [39,40].
196 Interestingly, the *Listeria* LLO toxin was recently shown to decrease the level of various E2
197 conjugases, in addition to UBC9, such as Ubiquitin E2s or the NEDD8 E2 UBC12/UBE2M
198 [41]. This suggests that several host Ubi/UBLs systems may be simultaneously altered in
199 response to *Listeria* infection.

200

201 *Secretion of bacterial effectors mimicking host Ubiquitin- and UBL- enzymes*

202 Besides interfering with ubiquitin or UBL-conjugation machineries, bacterial pathogens
203 produce proteins that can replace or act as components of these machineries (Fig. 1). In
204 particular, several bacterial effectors possess ubiquitin E3-like activity (Table 1). Some of these
205 bacterial effectors share structural homologies with the two major types of eukaryotic E3
206 ligases, *i.e.* the HECT type and the RING/U-box type E3 ligases [20,21,22]. These effectors
207 may have been acquired by bacteria via horizontal transfer from diverse eukaryotic sources
208 [42]. In addition to these types, three other classes of bacterial effectors display structures
209 completely distinct from eukaryotic E3 ligases: NELs (for Novel E3 ligase) [42], XL-box-
210 containing E3 ligases [43] and SidC ligase [44]. These ligases may represent structures evolved
211 by pathogens to mimic the functions of these essential host enzymes. The NELs family
212 encompasses effectors from different bacterial genera, including *Salmonella* (SlrP, SspH1 and

213 SspH2 effectors) and *Shigella* (IpaH family effectors) [20,42]. These enzymes possess an E2-
214 interacting domain, which hijacks host E2 charged with Ubi, a cysteine residue for Ubi transfer
215 and leucine-rich repeats (LRRs) allowing the recognition of a wide array of targets [20,42].
216 These different classes of E3 ligases enable bacteria to conjugate ubiquitin on specific host
217 factors, thereby altering their stability or function, subcellular localization or interaction with
218 other cellular proteins [20,22,42]. Bacterial E3 ligases may in particular conjugate K48-
219 ubiquitin chains to host proteins, thereby triggering their proteasome-dependent degradation.
220 By re-routing host factors to one of the most efficient proteolytic systems of the infected cell,
221 bacteria manage to eliminate key host components that normally interfere with their replication
222 and propagation [20,22]. Finally, bacterial E3 ligases can also target other bacterial effectors,
223 co-delivered during infection, allowing a tight restriction of their activity during a specific time
224 frame [21,22,45] (see below).

225 In contrast to bacterial effectors mimicking host ubiquitin enzymes, a family of proteins
226 secreted by the bacterial pathogen *Legionella pneumophila*, the causative agent of
227 Legionnaires' disease, was recently shown to catalyze the ubiquitination of host proteins
228 without the need for E1 and E2 ubiquitin enzymes [46-48]. The *Legionella* SdeA effector
229 belongs to this family of enzymes: it conjugates ubiquitin on endoplasmic reticulum (ER)-
230 associated Rab GTPases and participates in bacterial virulence [46,47,49]. By acting
231 independently of E1- and E2-ubiquitin enzymes, SdeA extends the repertoire of proteins
232 potentially modified by ubiquitin. Conjugation of ubiquitin on host targets by SdeA does not
233 rely on ATP and does not occur on lysines. SdeA instead uses NAD⁺ to mediate
234 phosphoribosyl-linked ubiquitination of serine residues in host proteins [46,47,49]. In addition
235 to ER-associated Rab GTPases, the *Legionella* effector SdeA and other members of the Sde
236 family ubiquitinate the host protein reticulon 4 (Rtn4), leading to ER reorganization and the
237 formation of *Legionella*-containing vacuoles, which are intracellular factories supporting

238 bacteria replication [48]. Unconventional ubiquitin conjugation by Sde effectors is reversible
239 as *L. pneumophila* codes for a specific deubiquitinase, SidJ, which removes phosphoribosylated
240 ubiquitin from its substrate [50]. Whether functional homologs of SdeA exist in eukaryotes and
241 what roles they may play remain to be determined.

242

243 *Deconjugation of Ubiquitin and UBL from host targets by bacterial effectors*

244 Another strategy used by bacteria to interfere with ubiquitin or UBL conjugation involves
245 secretion into host cells of effectors with isopeptidase activity, which removes ubiquitin or UBL
246 from their targets (Fig. 1 and Table 1). XopD, for example, is a T3SS effector secreted by the
247 plant pathogen *Xanthomonas euvesicatoria*, which possesses SUMO-specific isopeptidase
248 activity [51]. Upon infection of tomato cells, it deconjugates SUMO from the SIERF4
249 transcription factor to suppress host ethylene production, which constitutes an important
250 pathway for plants anti-bacterial immunity [52]. Many other bacterial proteases targeting
251 ubiquitin or UBLs have been identified in bacterial pathogens including *Salmonella*, *Shigella*,
252 *Chlamydia*, and *Legionella*, some of them being specific for one UBL while others display
253 cross-reactivity between different UBLs [53,54]. Interestingly, several bacterial effectors
254 possessing a deubiquitinase activity display a strong preference for K63-linked chains over K48
255 or K11 chains [54]. This may reveal a significant selection pressure for bacteria to interfere
256 with this specific ubiquitin-modification in order to promote infection.

257

258 *Direct targeting of Ubiquitin and UBL polypeptides*

259 Ubiquitin itself, as well as other UBLs, can be directly targeted and inactivated by bacterial
260 effectors (Fig. 1). Phosphoribosylation of ubiquitin for example, catalyzed by the *Legionella*
261 SdeA effector, was reported to interfere with multiple steps of the ubiquitination cascade [47].
262 The presence of phosphoribosylated ubiquitin in chains further confers resistance to various

263 deubiquitinases [55]. SdeA, by both triggering E1 and E2-independent ubiquitination of
264 specific host targets and by inhibiting ubiquitination of others, thus efficiently controls the host
265 ubiquitinome [47].

266

267 Ubiquitin and NEDD8 are also targeted by a family of bacterial T3SS effectors called Cifs (for
268 cycle inhibiting factors), produced by diverse pathogenic bacteria such as some EPEC or
269 *Burkholderia pseudomallei* [56]. Cifs directly target NEDD8 and ubiquitin and catalyse the
270 deamidation of the Gln⁴⁰ residue of these polypeptides [57]. Deamidation of ubiquitin interferes
271 with ubiquitin chain formation, whereas deamidation of NEDD8 blocks the activity of
272 neddylated Cullin-RING E3 ubiquitin ligases (CRLs) and impairs ubiquitination of several
273 CRL substrates in EPEC-infected cells [57,58]. Cifs inhibit in particular the ubiquitination of
274 Perforin-2/MPEG1 (Macrophage-expressed gene 1), an anti-microbial host protein forming
275 pores on bacteria cells, thereby blocking its intracellular trafficking and its bactericidal activity
276 [59].

277

278 **Main host pathways targeted by bacteria and regulated by Ubiquitin or UBLs**

279 During infection, bacterial pathogens alter the conjugation of ubiquitin or UBLs to many
280 different host proteins. These proteins belong to different pathways that are often essential for
281 bacteria to efficiently enter into host cells and replicate therein, or to dampen host anti-bacterial
282 responses. We here detail some of the pathways tightly regulated by Ubi/UBL modifications
283 and frequently targeted by bacterial pathogens.

284

285 *The NF- κ B pathway*

286 The NF- κ B pathway is an essential pillar of innate immunity and inflammation. Cytoplasmic
287 NF- κ B transcription factors are translocated into the nucleus within minutes after exposure to

288 bacteria-derived molecules and induce the transcription of a wide range of proinflammatory
289 chemokines and cytokines [12]. Not surprisingly, many bacterial effectors target the NF- κ B
290 pathway to dampen the host innate immune response. One given pathogen may in particular
291 produce several independent effectors targeting this pathway [12]. This apparent redundancy
292 of effectors, that all target the same signaling cascade, reflects the diversity of danger signals
293 sensed by the host that trigger this pathway.

294 One common strategy used by bacterial pathogens to dampen the NF- κ B signaling cascade
295 consists of conjugating K48-ubiquitin chains to essential components of this pathway, thereby
296 triggering their proteasome-dependent degradation [22]. *Shigella flexneri*, for example, uses at
297 least five different effectors that trigger ubiquitin-dependent degradation of diverse components
298 involved in essential branches of the NF- κ B pathway: IpaH1.4 and IpaH2.5 ubiquitinate the
299 catalytic component of the linear ubiquitin chain assembly complex (LUBAC) and trigger its
300 proteasomal degradation. Degradation of this component decreases LUBAC-mediated
301 ubiquitination of the NF- κ B modulator NEMO, which suppresses NF- κ B activation [60];
302 NEMO may also be directly ubiquitinated by IpaH9.8 [61]; IpaH0722 ubiquitinates TRAF2, a
303 factor involved in NF- κ B pathway activation following the detection of intracytosolic bacteria
304 [62].

305 Besides triggering proteasome-dependent degradation of components of the NF- κ B pathway,
306 bacterial pathogens also interfere with the endogenous ubiquitination of critical NF- κ B
307 regulators: as mentioned above, the *Shigella* OspI effector inhibits the host E2 enzyme UBC13,
308 thereby blocking TRAF6-mediated activation of the NF- κ B pathway [34]; OspG, another
309 *Shigella* effector, binds to and inhibits the host E2 ubiquitin enzyme UBCH5, involved in I κ B α
310 ubiquitination and subsequent degradation, which is a prerequisite for NF- κ B nuclear
311 translocation and NF- κ B-dependent gene transcription [63]; the NleB effector, encoded by
312 EPEC, possesses an N-acetylglucosamine transferase activity that modifies death domains in

313 several proteins such as FADD and TRADD and disrupts TNF signaling including NF- κ B
314 signaling [64,65]. Interference with the NF- κ B pathway may finally rely on the inhibition of
315 ubiquitin-binding proteins, that decode ubiquitin signals into biochemical cascades [11]. TAB2
316 and TAB3 are two ubiquitin-chain binding proteins involved in NF- κ B signaling. TAB2/3 bind
317 K63-linked polyubiquitin chains on target proteins and activate the I κ B α kinase, leading to
318 I κ B α phosphorylation, ubiquitination and degradation [66]. The NleE effector, secreted by
319 EPEC, is an S-adenosyl-L-methionine-dependent methyltransferase that specifically modifies
320 a zinc-finger cysteine in TAB2/3. This abolishes the binding of these proteins to ubiquitin-
321 chains and disrupts NF- κ B signaling [67].

322 The NF- κ B pathway thereby constitutes a nice example of the diverse mechanisms evolved by
323 bacteria to promote or inhibit ubiquitination of a large number of components in a coordinated
324 fashion, resulting in the dampening of an essential arm of the host anti-bacterial response. Of
325 course, these interfering strategies are not restricted to the NF- κ B pathway and other important
326 signaling cascades of the innate immune response, such as the IFN response or the activation
327 of inflammasome, can be similarly targeted [21,68]. The *Shigella* effector IpaH9.8, for
328 example, was reported to induce the degradation of other targets than NEMO such as GBPs
329 (Guanylate Binding Proteins) [69,70]. Following infection, GBPs are normally recruited to
330 bacteria-containing vacuoles or vacuole-escaped bacteria and participate to bacteria clearance.
331 IpaH9.8 ubiquitinates GBPs with K48-linked chains and target these proteins for proteasomal
332 degradation, thereby counteracting GBP-mediated inhibition of bacterial growth [69,70].

333

334 *Autophagy*

335 Autophagy is a cellular process by which intracellular cytosolic material is degraded by
336 lysosomes. Specific substrates, such as intracellular pathogens, can be tagged for targeting to
337 the autophagy pathway. They become encapsulated in *de novo*-generated double membrane

338 vesicles, called autophagosomes, that eventually fuse with lysosomes, leading to the
339 degradation of their contents [71,72]. This selective autophagy is essential for cell-autonomous
340 defense against bacteria invading the cytosol. Tagging of invading bacteria involve the
341 deposition of a ubiquitin coat constituted by multiple polyubiquitin chains. These ubiquitin
342 chains are synthesized by several host E3 ligases such as LRSAM1, Parkin, Smurf1, RNF166
343 or LUBAC [73-77]. These chains allow the recruitment of host cargo receptors that induce
344 autophagosome formation. The host E3 ligase LUBAC generates in particular linear ubiquitin
345 chains around intracytosolic bacteria that transform the bacterial surface into antibacterial and
346 pro-inflammatory signaling platforms [77]. Indeed, these LUBAC-synthesized ubiquitin chains
347 recruit host adaptors activating antibacterial immunity pathways such as the NF- κ B pathway.
348 Professional cytosol-dwelling bacteria have evolved evasion strategies to overcome restriction
349 by autophagy. Some of these strategies rely on interference with host ubiquitin. *Shigella*
350 *flexneri*, for example, remodel ubiquitin chains normally deposited by host ligases. It
351 antagonizes the deposition of linear ubiquitin chains by targeting LUBAC via the IpaH1.4
352 effector, thereby interfering with NF- κ B pathway activation [60,77]. Intracellular bacteria may
353 also evade autophagy by targeting ATG8, which regulates autophagosome biogenesis and
354 recruitment of specific cargos during selective autophagy [78]. ATG8 actually belong to the
355 UBL family along with SUMO, NEDD8 or ISG15. Interestingly, the RavZ effector from *L.*
356 *pneumophila* was shown to target ATG8 and to inhibit autophagy [79]. This effector cleaves
357 the amide bond between the C-terminal glycine residue and an adjacent aromatic residue in
358 ATG8. This produces an irreversibly inactivated form of ATG8 that cannot be re-conjugated
359 [79]. This example suggests that other UBLs than SUMO, NEDD8 and ISG15 may constitute
360 pivotal targets for pathogens to promote infection.

361

362 *Host cytoskeleton*

363 Remodeling of the host cytoskeleton is frequently used by intracellular bacterial pathogens to
364 enter into the targeted cells, create a niche where they can efficiently replicate, and disseminate
365 to neighboring cells [80]. Several components of the host cytoskeleton are regulated by
366 ubiquitin. RhoGTPases, for example, which control actin cytoskeleton dynamics, are degraded
367 by the proteasome following ubiquitin conjugation [81]. Interestingly, the ubiquitination level
368 of RhoGTPases can be modulated during *Salmonella* infection, suggesting that this bacterium
369 may modulate RhoGTPase turn-over [82]. SUMO can be conjugated to different components
370 of the host cytoskeleton as well, including actin itself and actin regulatory proteins, septins or
371 intermediate filaments such as keratins and lamins [83,84]. The role of ubiquitin and UBL
372 modifications in the regulation of the cytoskeleton is only in its infancy but one can anticipate
373 that it may represent an important target for bacterial pathogens to manipulate the cell
374 architecture.

375

376 *Transcription factors*

377 In order to exploit host functions, bacterial pathogens remodel the proteome of infected cells.
378 This remodeling may result from deregulation of gene transcription by injection of bacterial
379 proteins such as nucleomodulins that act directly on the host nucleus [85], or by interference
380 with host transcription factors, some of them being regulated by ubiquitin or UBLs. *L.*
381 *monocytogenes*, for example, dampens the SUMOylation of numerous transcription factors
382 during infection [36]. As SUMO conjugation either increases or decreases transcription factors
383 activity, this decrease in SUMOylation may modulate the expression of a specific subset of
384 genes and lead to a reprogramming of host gene expression. As mentioned above, decreasing
385 the SUMOylation of host transcription factors is a strategy also used by the plant pathogen
386 *Xanthomonas euvesicatoria* that specifically targets SUMO-SIERF4 to dampen the host
387 ethylene-mediated antibacterial response [52]. Finally, the colibactin toxin, produced by some

388 *Escherichia coli* strains in the intestine, induces a downregulation of the SUMO isopeptidase
389 SENP1 and an increase in the SUMOylation of the transcription factor p53. This ultimately
390 results in the emergence of senescent cells secreting growth factors that may promote colorectal
391 carcinogenesis [86].

392

393 *PML Nuclear Bodies*

394 PML (Promyelocytic Leukemia Protein) is a protein that polymerizes in discrete nuclear
395 assemblies known as PML nuclear bodies (NBs) and plays essential roles in many different
396 cellular processes [87]. Key to its function, PML can be post-translationally modified by SUMO
397 [87]. In addition to its role in anti-viral host defense [18], PML was recently identified as a
398 sensor for bacteria producing pore-forming toxins [37]. Indeed, intoxication of human cells by
399 the Listeriolysin O toxin, secreted by *L. monocytogenes*, triggers a massive deSUMOylation of
400 PML. This deSUMOylation of PML, coupled to an oxidative stress-dependent multimerization
401 of PML, initiates host cell anti-bacterial responses leading to a decrease in *Listeria* intracellular
402 replication [37]. This example of PML highlights how SUMO alterations of some specific host
403 proteins can constitute danger signals for the cells that triggers back anti-bacterial responses.
404 The putative role of PML in other bacterial infections targeting host SUMOylation, such as
405 *Shigella* or *Salmonella*, remains unknown but deserves further investigation.

406

407 **Post-translational modifications of bacterial proteins during infection**

408 Besides interfering with host protein post-translational modifications, bacteria can hijack host
409 ubiquitin or UBL-conjugation machineries to modify their own components (Fig. 1). As for
410 eukaryotic proteins, conjugation of ubiquitin or UBL has diverse effects on bacterial effectors
411 and may change their intracellular localization, their stability or their interaction with other
412 bacterial or host factors [88]. Post-translational modification of bacterial proteins couples their

413 activity to their arrival into the host cell cytoplasm. Interestingly, post-translational
414 modification of bacterial proteins can also be used by the host to tag exogenous proteins and
415 target them for degradation [88].

416 Ubiquitination of *Salmonella* proteins constitute nice examples illustrating the versatility of
417 consequences of this post-translational modification on bacterial proteins activity. SopE and
418 SptP are two *Salmonella* effectors that contribute to the transient remodeling of the host cell's
419 cytoskeleton [89]. These two effectors, which are delivered simultaneously by *Salmonella*,
420 exhibit different half-lives. SopE, which is involved in actin cytoskeleton rearrangement,
421 membrane ruffling and bacteria uptake, is rapidly polyubiquitinated and degraded by the host
422 proteasome [89]. SptP, which deactivates the RhoGTPases turned on by SopE, exhibits much
423 slower degradation kinetics, allowing recovery of the actin cytoskeleton's normal architecture
424 a few hours after infection [89]. Conjugation of ubiquitin to SopB, a phosphoinositide
425 phosphatase secreted by *Salmonella* via T3SS, modifies its cellular localization [90]. Upon
426 delivery, SopB associates with the host plasma membrane where it participates in actin-
427 mediated bacterial entry. Later on, ubiquitination of SopB by TRAF6 leads to its translocation
428 to *Salmonella*-containing vacuoles, where it modulates vesicle trafficking and interferes with
429 the delivery of these vacuoles to lysosomes [90,91]. Mass spectrometry-based large-scale
430 analysis of the ubiquitinome of cells infected by *Salmonella* recently provided additional
431 examples of bacterial proteins modified by ubiquitin [82]. In addition to SopE and SopB,
432 several effectors were identified as being ubiquitinated during infection [82]. Interestingly,
433 integral outer membrane proteins were reported to be conjugated to ubiquitin and may represent
434 the targets forming the ubiquitin coat that surrounds intracytosolic bacteria and is involved in
435 host anti-bacterial autophagy [71,82].

436 In contrast to ubiquitination, only a few bacterial proteins have been reported to be modified by
437 SUMO and the biological consequences of these modifications during infection often remains

438 elusive [92,93]. These SUMO-modified bacterial proteins include two effectors, TRP120 and
439 AmpA, secreted by two intracellular pathogens, *Ehrlichia chaffeensis* and *Anaplasma*
440 *phagocytophilum* respectively [92,93]. OspF, an effector secreted by *Shigella flexneri*,
441 constitutes another example for which SUMO conjugation is required for the translocation of
442 this effector into the host nucleus where it modulates the expression of proinflammatory
443 cytokines [94].

444 One can anticipate that recently developed techniques for large scale proteomic studies of UBL
445 conjugation will increase the list of bacterial proteins modified by SUMO or other UBLs, and
446 provide new insights for the role of these modifications during infection.

447

448 **Concluding Remarks**

449 Ubiquitin and UBL are essential post-translational modifiers of eukaryotic cells. Thousands of
450 Ubi/UBL targets have been identified during recent years, suggesting that most proteins will be
451 modified by this type of PTM at some point in their cellular lifetime. It is thus not surprising
452 that pathogens have evolved so many strategies to interfere with these particular PTMs in order
453 to manipulate host cell physiology. Interfering with host Ubi/UBL modifications is observed
454 both for intracellular pathogens, that tightly interact with host cell cytoplasmic components to
455 create for example a protective niche where they can acquire nutrients from the host, and for
456 extracellular pathogens, that manipulate host cells to favor their maintenance at the surface of
457 the cells or dampen host immune responses.

458 Two types of interfering strategies used by bacterial pathogens can be distinguished: they may
459 either globally dampen Ubi/UBL systems, by targeting the conjugation machineries or by
460 modifying the equilibrium between conjugation/deconjugation reactions, or they may alter the
461 level of Ubi/UBL-conjugation of only specific host proteins involved in bacterial proliferation
462 and antibacterial responses. In the case of global dampening of Ubi/UBL systems, a wide range

463 of host proteins display altered levels of Ubi/UBL conjugation. Discrimination, in this pool of
464 proteins, of host factors directly involved in infection from other factors that only represent “co-
465 lateral damages” may constitute a real challenge to study the exact role of these PTMs during
466 infection.

467 Thanks to the continuous improvement in proteomic analyses, the list of proteins known to be
468 modified by ubiquitin or UBLs has greatly expanded during these last years. For example, it is
469 now feasible to compare the variations of the ubiquitinome (or other “UBL-ome”) of cells
470 during infection by a pathogen or after exposure to a bacterial toxin [36,82]. Some of these
471 techniques are furthermore compatible with *in vivo* analysis and the comparison of the content
472 of proteins modified by Ubi/UBL in organs from infected or control animals is now possible
473 [95,96]. Interestingly, current proteomic-based approaches have not only revealed the identity
474 of the proteins modified by Ubi/UBL but also the modification sites. These data are critical for
475 further analysis of the role of these PTMs in the function of the identified protein and hence, to
476 decipher the consequences of bacterial alteration of these PTMs. Several recent studies on
477 ubiquitin conjugation have revealed that ubiquitination establishes a much more complex code
478 than originally thought. Indeed, in addition to “mixed” ubiquitin chains involving different
479 types of linkages between ubiquitin monomers, chains that mix ubiquitin with other UBLs such
480 as SUMO have also been reported [4,27,97]. In addition, ubiquitin has recently been found to
481 be itself post-translationally modified by acetylation or phosphorylation, which further expands
482 the repertoire of ubiquitination [4,27,97]. We are only beginning to understand the tremendous
483 diversity of ubiquitin modifications and their roles in cell biology but it is very likely that
484 bacterial pathogens have long learned how to break this so-called “ubiquitin code” and
485 efficiently use it for their own profit (see Outstanding Questions).

486 Finally, while this review has focused on pathogenic bacteria, some non-pathogenic
487 bacteria such as commensals of the intestinal microbiota were also reported to interfere with

488 host Ubi/UBL systems [98]. For example, production of butyrate by commensal bacteria leads
489 to the inactivation of the E2 NEDD8 enzyme in intestinal epithelial cells and was proposed to
490 participate in the inflammatory tolerance of gut bacteria [99,100].

491 Manipulation of Ubi/UBL conjugation by pathogenic bacteria constitute a key facet of
492 host-pathogen interactions. Studying how bacteria interfere with these PTM is essential to
493 complete our understanding of the infection process. In particular, identification of bacterial
494 effectors harboring non-eukaryotic enzymatic activities and manipulating host Ubi/UBL may
495 provide potential new drug targets, which is critical in this age of bacterial resistance to
496 antibiotics.

497 **Figure 1, Key Figure : Main strategies used by bacterial pathogens to interfere with host**
498 **ubiquitin or ubiquitin-like protein modifications.**

499 During infection, bacteria may inhibit or trigger the degradation of Ubi/UBL enzymes such as
500 E1 activating enzymes, E2 conjugating enzymes or E3 ligases (1). These effects can be directly
501 triggered by bacterial effectors, or indirectly via the induction of host signaling cascades
502 (dashed lines). Bacteria may also secrete effectors possessing either E3 ligase activity, which
503 conjugate Ubi/UBL to host targets (2), or isopeptidase activity, which remove Ubi/UBL from
504 their targets (3). Bacteria may also directly modify ubiquitin or UBLs to block their conjugation
505 to host targets (4). Finally, bacteria may hijack the host Ubi/UBL systems to modify their own
506 proteins during infection (5). Red arrows, proteins secreted by bacteria.

507 **Table 1 : Examples of bacterial proteins interfering with Ubi/UBL conjugation to host proteins**

508

Ubi/UBL target	Bacteria	Extra/intracellular bacteria	Effector	Enzymatic activity	Effect	Refs
Ubiquitin	<i>Salmonella Typhimurium</i>	intracellular	SopA	E3 Ubi ligase (HECT)	Regulation of host inflammation	[67]
Ubiquitin	EPEC, EHEC	extracellular	NleL	E3 Ubi ligase (HECT)	Regulation of actin pedestal formation	[101]
Ubiquitin	EPEC, EHEC	extracellular	NleG	E3 Ubi ligase (RING)	?	[102]
Ubiquitin	<i>Pseudomonas syringae</i>	extracellular	AvrPtoB	E3 Ubi ligase (U-box)	Inhibition of plant pattern-triggered immunity	[103,104]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	OspI	Gln deamidase	Inactivation of UBE2N/UBC13 (E2 Ubi enzyme NF- κ B pathway)	[34]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	IpaH1.4	E3 Ubi ligase (NEL)	Ubiquitination of LUBAC (NF- κ B pathway)	[60]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	IpaH2.5	E3 Ubi ligase (NEL)	Ubiquitination of LUBAC (NF- κ B pathway)	[60]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	IpaH0722	E3 Ubi ligase (NEL)	Ubiquitination of TRAF2 (NF- κ B pathway)	[62]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	IpaH9.8	E3 Ubi ligase (NEL)	Ubiquitination of NEMO (NF- κ B pathway)	[61]
Ubiquitin	<i>Salmonella Typhimurium</i>	intracellular	Ssph1	E3 Ubi ligase (NEL)	Ubiquitination of PKN1 (NF- κ B pathway)	[105]
Ubiquitin	<i>Legionella pneumophila</i>	intracellular	SdeA	non eukaryotic Ubi ligase	E1/E2-independent ubiquitination of Rab GTPases and RTN4	[46-48]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	OspG	kinase	Inhibition of UBCH5 (E2 Ubi enzyme; NF- κ B pathway)	[63]
Ubiquitin	EPEC, EHEC	extracellular	NleB	Glycosyltransferase	Inhibition of TRAF2 ubiquitination (NF- κ B pathway)	[106]
Ubiquitin	EPEC	extracellular	?	?	Downregulation of UBE1 and UBA6 (E1 Ubi enzymes)	[35]

Ubiquitin	EPEC	extracellular	NleE	Cys methyltransferase	Inactivation of TAB2 and TAB3 (NF-κB pathway)	[67,107]
Ubiquitin	<i>Legionella pneumophila</i>	intracellular	SidJ	deubiquitylase	?	[50]
Ubiquitin	<i>Shigella flexneri</i>	intracellular	ShiCE	deubiquitylase	?	[54]
Ubiquitin	<i>Chlamydia trachomatis</i>	intracellular	ChlaDUB1	deubiquitylase	Inhibition of NF-κB pathway activation	[108,109]
Ubiquitin	<i>Burkholderia pseudomallei</i>	extracellular	CHBP	Gln deamidase	Deamidation of Ubiquitin	[57]
SUMO	<i>Listeria monocytogenes</i>	intracellular	LLO	Pore-forming toxin	Downregulation of UBE2I/UBC9 (E2 SUMO enzyme)	[25]
SUMO	<i>Clostridium perfringens</i>	extracellular	PFO	Pore-forming toxin	Downregulation of UBE2I/UBC9 (E2 SUMO enzyme)	[25]
SUMO	<i>Streptococcus pneumoniae</i>	extracellular	PLY	Pore-forming toxin	Downregulation of UBE2I/UBC9 (E2 SUMO enzyme)	[25]
SUMO	<i>Shigella flexneri</i>	intracellular	? / Ca ²⁺ influx	?	Proteolytic cleavage of UBA2/SAE2 (E1 SUMO enzyme)	[39]
SUMO	<i>Salmonella Typhimurium</i>	intracellular	? / miRNAs	?	Downregulation of UBE2I/UBC9 (E2 SUMO enzyme)	[38]
SUMO	<i>Xanthomonas euvesicatoria</i>	extracellular	XopD	deSUMOylase	DeSUMOylation of SIERF4 (plant immune response)	[51,52]
NEDD8	EPEC	extracellular	CIF	Gln deamidase	Deamidation of NEDD8	[57,58]
NEDD8	<i>Chlamydia trachomatis</i>	intracellular	ChlaDUB1	deNeddylase	Inhibition of NF-κB pathway activation	[108,109]

509

510 EPEC, Enteropathogenic *Escherichia coli*. EHEC, Enterohaemorrhagic *Escherichia coli*. HECT, homologous to the E6-AP carboxyl terminus. RING, really interesting new

511 genes. NEL, Novel E3 ligase. ?, not determined.

512 **Text Box 1**

513 Even if bacteria do not encode Ubiquitin, two types of bacterial polypeptides that can be linked
514 to target proteins via isopeptide bonds have been reported [110,111]. The first type of bacterial
515 modifier is called Pup (for prokaryotic ubiquitin-like protein) and is restricted to specific
516 bacterial phyla such *Actinobacteria*. Pupylation, *i.e.* the covalent fixation of Pup to target
517 proteins is a fascinating example of convergent evolution with respect to eukaryotic
518 ubiquitination. It involves an enzymatic machinery distinct from ubiquitination, that deamidates
519 Pup C-terminal Gln before linking it to target lysine residues [110,111]. This covalent
520 modification targets bacterial proteins to proteasomal degradation. Several hundred of
521 pupylated targets have been identified to date, which are involved in a variety of pathways. In
522 *Mycobacterium tuberculosis*, pupylation is essential for the survival of bacteria in the host and
523 may thus constitute an interesting drug target,[110-112]. The second type of bacterial modifiers
524 is constituted by polypeptides that differ from Ubi in sequence but share a common structural
525 β -grasp fold [110]. These Ubi-fold proteins include the archeal SAMPs (small archeal modifier
526 proteins) and *Thermus* TtuB (tRNA-two-thiouridine B) that function both as protein modifiers
527 and sulfur carriers for sulfur-containing biomolecules synthesis [110]. Bacterial Ubi-fold
528 proteins linkage to lysine residues in target proteins involves ubiquitin E1 homologs but not
529 canonical E2 or E3 ubiquitin-like enzymes [110].

530 In addition to these modifiers analogous to ubiquitin, some human commensal bacteria may
531 even usurp eukaryotic ubiquitin for their own purpose. Indeed, an ubiquitin gene has been
532 identified in the genome of *Bacteroides fragilis* strains [113,114]. Interestingly, this eukaryotic-
533 like ubiquitin, which was probably acquired via horizontal gene transfer, does not seem to be
534 involved in bacterial protein modification since it lacks the critical terminal glycine residue.
535 This protein is instead secreted and acts as a bacterial toxin targeting and killing other intestinal
536 bacteria [114]. Many other surprises like this one are probably still awaiting to be discovered

537 and, even though the first report of a bacterium post-translationally modifying a host protein
538 occurred almost 50 years ago [115], the field of pathogen and host post-translational
539 modifications is, without a doubt, still very promising.

540

541 **Acknowledgments**

542 We apologize to all colleagues whose work we were unable to include due to space
543 constraints. We thank L. Radoshevich for the critical reading of this manuscript. P.C. received
544 support from Institut Pasteur, INSERM, INRA, the French National Research Agency (ANR)
545 (ERANET Infect-ERA PROANTILIS ANR-13-IFEC-0004-02), the French Government's
546 Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging
547 Infectious Diseases" (ANR-10-LABX-62-IBEID), the European Research Council (ERC)
548 (H2020-ERC-2014-ADG 670823-BacCellEpi), the Fondation le Roch les Mousquetaires, the
549 Fondation Louis-Jeantet and the International Balzan Prize Fondation. P.C. is a Senior
550 International Research Scholar of the Howard Hughes Medical Institute. D.R. received support
551 from INSERM, Rouen University and the iXcore Foundation for Research.

552

553 **REFERENCES**

- 554 1. Ribet, D. and Cossart, P. (2010) Post-translational modifications in host cells during bacterial
555 infection. *FEBS Lett* 584 (13), 2748-58.
- 556 2. Deribe, Y.L. et al. (2010) Post-translational modifications in signal integration. *Nat Struct Mol Biol*
557 17 (6), 666-72.
- 558 3. Goldstein, G. et al. (1975) Isolation of a polypeptide that has lymphocyte-differentiating properties
559 and is probably represented universally in living cells. *Proc Natl Acad Sci U S A* 72 (1), 11-5.
- 560 4. Swatek, K.N. and Komander, D. (2016) Ubiquitin modifications. *Cell Res* 26 (4), 399-422.
- 561 5. Kwon, Y.T. and Ciechanover, A. (2017) The Ubiquitin Code in the Ubiquitin-Proteasome System
562 and Autophagy. *Trends Biochem Sci* 42 (11), 873-886.
- 563 6. Flotho, A. and Melchior, F. (2013) Sumoylation: a regulatory protein modification in health and
564 disease. *Annu Rev Biochem* 82, 357-85.

565 7. Enchev, R.I. et al. (2015) Protein neddylation: beyond cullin-RING ligases. *Nat Rev Mol Cell Biol*
566 16 (1), 30-44.

567 8. Villarroya-Beltri, C. et al. (2017) ISGylation - a key to lock the cell gates for preventing the spread
568 of threats. *J Cell Sci* 130 (18), 2961-2969.

569 9. Basler, M. et al. (2015) The ubiquitin-like modifier FAT10 in antigen processing and antimicrobial
570 defense. *Mol Immunol* 68 (2 Pt A), 129-32.

571 10. Streich, F.C., Jr. and Lima, C.D. (2014) Structural and functional insights to ubiquitin-like protein
572 conjugation. *Annu Rev Biophys* 43, 357-79.

573 11. Husnjak, K. and Dikic, I. (2012) Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular
574 functions. *Annu Rev Biochem* 81, 291-322.

575 12. Rahman, M.M. and McFadden, G. (2011) Modulation of NF-kappaB signalling by microbial
576 pathogens. *Nat Rev Microbiol* 9 (4), 291-306.

577 13. Decque, A. et al. (2016) Sumoylation coordinates the repression of inflammatory and anti-viral gene-
578 expression programs during innate sensing. *Nat Immunol* 17 (2), 140-9.

579 14. Bogunovic, D. et al. (2012) Mycobacterial disease and impaired IFN-gamma immunity in humans
580 with inherited ISG15 deficiency. *Science* 337 (6102), 1684-8.

581 15. Radoshevich, L. et al. (2015) ISG15 counteracts *Listeria monocytogenes* infection. *Elife* 4.

582 16. Spinnenhirn, V. et al. (2014) The ubiquitin-like modifier FAT10 decorates autophagy-targeted
583 *Salmonella* and contributes to *Salmonella* resistance in mice. *J Cell Sci* 127 (Pt 22), 4883-93.

584 17. Ribet, D. and Cossart, P. (2010) Pathogen-mediated posttranslational modifications: A re-emerging
585 field. *Cell* 143 (5), 694-702.

586 18. Everett, R.D. et al. (2013) Interplay between viruses and host sumoylation pathways. *Nat Rev*
587 *Microbiol* 11 (6), 400-11.

588 19. Wimmer, P. and Schreiner, S. (2015) Viral Mimicry to Usurp Ubiquitin and SUMO Host Pathways.
589 *Viruses* 7 (9), 4854-72.

590 20. Maculins, T. et al. (2016) Bacteria-host relationship: ubiquitin ligases as weapons of invasion. *Cell*
591 *Res* 26 (4), 499-510.

592 21. Ashida, H. and Sasakawa, C. (2017) Bacterial E3 ligase effectors exploit host ubiquitin systems.
593 *Curr Opin Microbiol* 35, 16-22.

594 22. Lin, Y.H. and Machner, M.P. (2017) Exploitation of the host cell ubiquitin machinery by microbial
595 effector proteins. *J Cell Sci* 130 (12), 1985-1996.

596 23. Wilson, V.G. (2017) Viral Interplay with the Host Sumoylation System. *Adv Exp Med Biol* 963,
597 359-388.

598 24. Maruthi, M. et al. (2017) Modulation of host cell SUMOylation facilitates efficient development of
599 *Plasmodium berghei* and *Toxoplasma gondii*. *Cell Microbiol* 19 (7).

600 25. Ribet, D. et al. (2010) *Listeria monocytogenes* impairs SUMOylation for efficient infection. *Nature*
601 464 (7292), 1192-5.

- 602 26. Galan, J.E. and Waksman, G. (2018) Protein-Injection Machines in Bacteria. *Cell* 172 (6), 1306-
603 1318.
- 604 27. Yau, R. and Rape, M. (2016) The increasing complexity of the ubiquitin code. *Nat Cell Biol* 18 (6),
605 579-86.
- 606 28. Hrdinka, M. and Gyrd-Hansen, M. (2017) The Met1-Linked Ubiquitin Machinery: Emerging
607 Themes of (De)regulation. *Mol Cell* 68 (2), 265-280.
- 608 29. Zheng, N. and Shabek, N. (2017) Ubiquitin Ligases: Structure, Function, and Regulation. *Annu Rev*
609 *Biochem* 86, 129-157.
- 610 30. Hatakeyama, S. et al. (2001) U box proteins as a new family of ubiquitin-protein ligases. *J Biol*
611 *Chem* 276 (35), 33111-20.
- 612 31. Walden, H. and Rittinger, K. (2018) RBR ligase-mediated ubiquitin transfer: a tale with many twists
613 and turns. *Nat Struct Mol Biol*.
- 614 32. Pao, K.C. et al. (2018) Activity-based E3 ligase profiling uncovers an E3 ligase with esterification
615 activity. *Nature* 556 (7701), 381-385.
- 616 33. Mevissen, T.E.T. and Komander, D. (2017) Mechanisms of Deubiquitinase Specificity and
617 Regulation. *Annu Rev Biochem* 86, 159-192.
- 618 34. Sanada, T. et al. (2012) The *Shigella flexneri* effector OspI deamidates UBC13 to dampen the
619 inflammatory response. *Nature* 483 (7391), 623-6.
- 620 35. Lin, A.E. and Guttman, J.A. (2012) The *Escherichia coli* adherence factor plasmid of
621 enteropathogenic *Escherichia coli* causes a global decrease in ubiquitylated host cell proteins by
622 decreasing ubiquitin E1 enzyme expression through host aspartyl proteases. *Int J Biochem Cell Biol* 44
623 (12), 2223-32.
- 624 36. Impens, F. et al. (2014) Mapping of SUMO sites and analysis of SUMOylation changes induced by
625 external stimuli. *Proc Natl Acad Sci U S A* 111 (34), 12432-7.
- 626 37. Ribet, D. et al. (2017) Promyelocytic Leukemia Protein (PML) Controls *Listeria monocytogenes*
627 Infection. *MBio* 8 (1).
- 628 38. Verma, S. et al. (2015) *Salmonella* Engages Host MicroRNAs To Modulate SUMOylation: a New
629 Arsenal for Intracellular Survival. *Mol Cell Biol* 35 (17), 2932-46.
- 630 39. Lapaquette, P. et al. (2017) *Shigella* entry unveils a calcium/calpain-dependent mechanism for
631 inhibiting sumoylation. *Elife* 6.
- 632 40. Fritah, S. et al. (2014) Sumoylation controls host anti-bacterial response to the gut invasive pathogen
633 *Shigella flexneri*. *EMBO Rep* 15 (9), 965-72.
- 634 41. Malet, J.K. et al. (2018) Rapid remodeling of the host epithelial cell proteome by the listeriolysin O
635 pore-forming toxin. *Mol Cell Proteomics* (in press).
- 636 42. Hicks, S.W. and Galan, J.E. (2010) Hijacking the host ubiquitin pathway: structural strategies of
637 bacterial E3 ubiquitin ligases. *Curr Opin Microbiol* 13 (1), 41-6.

638 43. Singer, A.U. et al. (2013) A pathogen type III effector with a novel E3 ubiquitin ligase architecture.
639 PLoS Pathog 9 (1), e1003121.

640 44. Hsu, F. et al. (2014) The *Legionella* effector SidC defines a unique family of ubiquitin ligases
641 important for bacterial phagosomal remodeling. Proc Natl Acad Sci U S A 111 (29), 10538-43.

642 45. Kubori, T. et al. (2010) *Legionella* metaeffector exploits host proteasome to temporally regulate
643 cognate effector. PLoS Pathog 6 (12), e1001216.

644 46. Qiu, J. et al. (2016) Ubiquitination independent of E1 and E2 enzymes by bacterial effectors. Nature
645 533 (7601), 120-4.

646 47. Bhogaraju, S. et al. (2016) Phosphoribosylation of Ubiquitin Promotes Serine Ubiquitination and
647 Impairs Conventional Ubiquitination. Cell 167 (6), 1636-1649 e13.

648 48. Kotewicz, K.M. et al. (2017) A Single *Legionella* Effector Catalyzes a Multistep Ubiquitination
649 Pathway to Rearrange Tubular Endoplasmic Reticulum for Replication. Cell Host Microbe 21 (2), 169-
650 181.

651 49. Kalayil, S. et al. (2018) Insights into catalysis and function of phosphoribosyl-linked serine
652 ubiquitination. Nature 557 (7707), 734-738.

653 50. Qiu, J. et al. (2017) A unique deubiquitinase that deconjugates phosphoribosyl-linked protein
654 ubiquitination. Cell Res 27 (7), 865-881.

655 51. Hotson, A. et al. (2003) *Xanthomonas* type III effector XopD targets SUMO-conjugated proteins in
656 planta. Mol Microbiol 50 (2), 377-89.

657 52. Kim, J.G. et al. (2013) *Xanthomonas* type III effector XopD desumoylates tomato transcription
658 factor SIERF4 to suppress ethylene responses and promote pathogen growth. Cell Host Microbe 13 (2),
659 143-54.

660 53. Sheedlo, M.J. et al. (2015) Structural basis of substrate recognition by a bacterial deubiquitinase
661 important for dynamics of phagosome ubiquitination. Proc Natl Acad Sci U S A 112 (49), 15090-5.

662 54. Pruneda, J.N. et al. (2016) The Molecular Basis for Ubiquitin and Ubiquitin-like Specificities in
663 Bacterial Effector Proteases. Mol Cell 63 (2), 261-276.

664 55. Puvar, K. et al. (2017) Ubiquitin Chains Modified by the Bacterial Ligase SdeA Are Protected from
665 Deubiquitinase Hydrolysis. Biochemistry 56 (36), 4762-4766.

666 56. Taieb, F. et al. (2011) Cycle inhibiting factors (cifs): cyclomodulins that usurp the ubiquitin-
667 dependent degradation pathway of host cells. Toxins (Basel) 3 (4), 356-68.

668 57. Cui, J. et al. (2010) Glutamine deamidation and dysfunction of ubiquitin/NEDD8 induced by a
669 bacterial effector family. Science 329 (5996), 1215-8.

670 58. Yu, C. et al. (2015) Gln40 deamidation blocks structural reconfiguration and activation of SCF
671 ubiquitin ligase complex by Nedd8. Nat Commun 6, 10053.

672 59. McCormack, R.M. et al. (2015) Enteric pathogens deploy cell cycle inhibiting factors to block the
673 bactericidal activity of Perforin-2. Elife 4.

674 60. de Jong, M.F. et al. (2016) *Shigella flexneri* suppresses NF-kappaB activation by inhibiting linear
675 ubiquitin chain ligation. Nat Microbiol 1 (7), 16084.

676 61. Ashida, H. et al. (2010) A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to
677 dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol 12 (1), 66-73; sup pp 1-9.

678 62. Ashida, H. et al. (2013) *Shigella* IpaH0722 E3 ubiquitin ligase effector targets TRAF2 to inhibit
679 PKC-NF-kappaB activity in invaded epithelial cells. PLoS Pathog 9 (6), e1003409.

680 63. Kim, D.W. et al. (2005) The *Shigella flexneri* effector OspG interferes with innate immune responses
681 by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A 102 (39), 14046-51.

682 64. Li, S. et al. (2013) Pathogen blocks host death receptor signalling by arginine GlcNAcylation of
683 death domains. Nature 501 (7466), 242-6.

684 65. Pearson, J.S. et al. (2013) A type III effector antagonizes death receptor signalling during bacterial
685 gut infection. Nature 501 (7466), 247-51.

686 66. Kanayama, A. et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to
687 polyubiquitin chains. Mol Cell 15 (4), 535-48.

688 67. Zhang, L. et al. (2011) Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB
689 activation. Nature 481 (7380), 204-8.

690 68. Suzuki, S. et al. (2014) *Shigella* IpaH7.8 E3 ubiquitin ligase targets glomulin and activates
691 inflammasomes to demolish macrophages. Proc Natl Acad Sci U S A 111 (40), E4254-63.

692 69. Wandel, M.P. et al. (2017) GBPs Inhibit Motility of *Shigella flexneri* but Are Targeted for
693 Degradation by the Bacterial Ubiquitin Ligase IpaH9.8. Cell Host Microbe 22 (4), 507-518 e5.

694 70. Li, P. et al. (2017) Ubiquitination and degradation of GBPs by a *Shigella* effector to suppress host
695 defence. Nature 551 (7680), 378-383.

696 71. Veiga, E. and Cossart, P. (2005) Ubiquitination of intracellular bacteria: a new bacteria-sensing
697 system? Trends Cell Biol 15 (1), 2-5.

698 72. Boyle, K.B. and Randow, F. (2013) The role of 'eat-me' signals and autophagy cargo receptors in
699 innate immunity. Curr Opin Microbiol 16 (3), 339-48.

700 73. Huett, A. et al. (2012) The LRR and RING domain protein LRSAM1 is an E3 ligase crucial for
701 ubiquitin-dependent autophagy of intracellular *Salmonella Typhimurium*. Cell Host Microbe 12 (6),
702 778-90.

703 74. Manzanillo, P.S. et al. (2013) The ubiquitin ligase parkin mediates resistance to intracellular
704 pathogens. Nature 501 (7468), 512-6.

705 75. Franco, L.H. et al. (2017) The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of
706 *Mycobacterium tuberculosis* and Anti-tuberculous Host Defense. Cell Host Microbe 21 (1), 59-72.

707 76. Heath, R.J. et al. (2016) RNF166 Determines Recruitment of Adaptor Proteins during Antibacterial
708 Autophagy. Cell Rep 17 (9), 2183-2194.

709 77. Noad, J. et al. (2017) LUBAC-synthesized linear ubiquitin chains restrict cytosol-invading bacteria
710 by activating autophagy and NF-kappaB. Nat Microbiol 2, 17063.

711 78. Klionsky, D.J. and Schulman, B.A. (2014) Dynamic regulation of macroautophagy by distinctive
712 ubiquitin-like proteins. *Nat Struct Mol Biol* 21 (4), 336-45.

713 79. Choy, A. et al. (2012) The *Legionella* effector RavZ inhibits host autophagy through irreversible
714 Atg8 deconjugation. *Science* 338 (6110), 1072-6.

715 80. de Souza Santos, M. and Orth, K. (2015) Subversion of the cytoskeleton by intracellular bacteria:
716 lessons from *Listeria*, *Salmonella* and *Vibrio*. *Cell Microbiol* 17 (2), 164-73.

717 81. Nethe, M. and Hordijk, P.L. (2010) The role of ubiquitylation and degradation in RhoGTPase
718 signalling. *J Cell Sci* 123 (Pt 23), 4011-8.

719 82. Fiskin, E. et al. (2016) Global Analysis of Host and Bacterial Ubiquitinome in Response to
720 *Salmonella* Typhimurium Infection. *Mol Cell* 62 (6), 967-981.

721 83. Alonso, A. et al. (2015) Emerging roles of sumoylation in the regulation of actin, microtubules,
722 intermediate filaments, and septins. *Cytoskeleton (Hoboken)* 72 (7), 305-39.

723 84. Ribet, D. et al. (2017) SUMOylation of human septins is critical for septin filament bundling and
724 cytokinesis. *J Cell Biol* 216 (12), 4041-4052.

725 85. Bierne, H. and Cossart, P. (2012) When bacteria target the nucleus: the emerging family of
726 nucleomodulins. *Cell Microbiol* 14 (5), 622-33.

727 86. Cougnoux, A. et al. (2014) Bacterial genotoxin colibactin promotes colon tumour growth by
728 inducing a senescence-associated secretory phenotype. *Gut* 63 (12), 1932-42.

729 87. Lallemand-Breitenbach, V. and de The, H. (2018) PML nuclear bodies: from architecture to
730 function. *Curr Opin Cell Biol* 52, 154-161.

731 88. Popa, C.M. et al. (2016) Modification of Bacterial Effector Proteins Inside Eukaryotic Host Cells.
732 *Front Cell Infect Microbiol* 6, 73.

733 89. Kubori, T. and Galan, J.E. (2003) Temporal regulation of *Salmonella* virulence effector function by
734 proteasome-dependent protein degradation. *Cell* 115 (3), 333-42.

735 90. Patel, J.C. et al. (2009) Diversification of a *Salmonella* virulence protein function by ubiquitin-
736 dependent differential localization. *Cell* 137 (2), 283-94.

737 91. Knodler, L.A. et al. (2009) Ubiquitination of the bacterial inositol phosphatase, SopB, regulates its
738 biological activity at the plasma membrane. *Cell Microbiol* 11 (11), 1652-70.

739 92. Dunphy, P.S. et al. (2014) *Ehrlichia chaffeensis* exploits host SUMOylation pathways to mediate
740 effector-host interactions and promote intracellular survival. *Infect Immun* 82 (10), 4154-68.

741 93. Beyer, A.R. et al. (2015) The *Anaplasma phagocytophilum* effector AmpA hijacks host cell
742 SUMOylation. *Cell Microbiol* 17 (4), 504-19.

743 94. Jo, K. et al. (2017) Host Cell Nuclear Localization of *Shigella flexneri* Effector OspF Is Facilitated
744 by SUMOylation. *J Microbiol Biotechnol* 27 (3), 610-615.

745 95. Xu, G. et al. (2010) Global analysis of lysine ubiquitination by ubiquitin remnant immunoaffinity
746 profiling. *Nat Biotechnol* 28 (8), 868-73.

747 96. Becker, J. et al. (2013) Detecting endogenous SUMO targets in mammalian cells and tissues. Nat
748 Struct Mol Biol 20 (4), 525-31.

749 97. Herhaus, L. and Dikic, I. (2015) Expanding the ubiquitin code through post-translational
750 modification. EMBO Rep 16 (9), 1071-83.

751 98. Collier-Hyams, L.S. et al. (2005) Cutting edge: bacterial modulation of epithelial signaling via
752 changes in neddylation of cullin-1. J Immunol 175 (7), 4194-8.

753 99. Kumar, A. et al. (2007) Commensal bacteria modulate cullin-dependent signaling via generation of
754 reactive oxygen species. EMBO J 26 (21), 4457-66.

755 100. Kumar, A. et al. (2009) The bacterial fermentation product butyrate influences epithelial signaling
756 via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 182 (1), 538-46.

757 101. Piscatelli, H. et al. (2011) The EHEC type III effector NleL is an E3 ubiquitin ligase that modulates
758 pedestal formation. PLoS One 6 (4), e19331.

759 102. Wu, B. et al. (2010) NleG Type 3 effectors from enterohaemorrhagic Escherichia coli are U-Box
760 E3 ubiquitin ligases. PLoS Pathog 6 (6), e1000960.

761 103. Janjusevic, R. et al. (2006) A bacterial inhibitor of host programmed cell death defenses is an E3
762 ubiquitin ligase. Science 311 (5758), 222-6.

763 104. Abramovitch, R.B. et al. (2006) Type III effector AvrPtoB requires intrinsic E3 ubiquitin ligase
764 activity to suppress plant cell death and immunity. Proc Natl Acad Sci U S A 103 (8), 2851-6.

765 105. Rohde, J.R. et al. (2007) Type III secretion effectors of the IpaH family are E3 ubiquitin ligases.
766 Cell Host Microbe 1 (1), 77-83.

767 106. Gao, X. et al. (2013) NleB, a bacterial effector with glycosyltransferase activity, targets GAPDH
768 function to inhibit NF-kappaB activation. Cell Host Microbe 13 (1), 87-99.

769 107. Nadler, C. et al. (2010) The type III secretion effector NleE inhibits NF-kappaB activation. PLoS
770 Pathog 6 (1), e1000743.

771 108. Misaghi, S. et al. (2006) *Chlamydia trachomatis*-derived deubiquitinating enzymes in mammalian
772 cells during infection. Mol Microbiol 61 (1), 142-50.

773 109. Le Negrato, G. et al. (2008) ChlaDub1 of *Chlamydia trachomatis* suppresses NF-kappaB activation
774 and inhibits IkappaBalpha ubiquitination and degradation. Cell Microbiol 10 (9), 1879-92.

775 110. Maupin-Furlow, J.A. (2014) Prokaryotic ubiquitin-like protein modification. Annu Rev Microbiol
776 68, 155-75.

777 111. Delley, C.L. et al. (2017) Prokaryotic Ubiquitin-Like Protein and Its Ligase/Delignase Enzymes. J
778 Mol Biol 429 (22), 3486-3499.

779 112. Gandotra, S. et al. (2010) The *Mycobacterium tuberculosis* proteasome active site threonine is
780 essential for persistence yet dispensable for replication and resistance to nitric oxide. PLoS Pathog 6
781 (8), e1001040.

- 782 113. Patrick, S. et al. (2011) A unique homologue of the eukaryotic protein-modifier ubiquitin present
783 in the bacterium *Bacteroides fragilis*, a predominant resident of the human gastrointestinal tract.
784 Microbiology 157 (Pt 11), 3071-8.
- 785 114. Chatzidaki-Livanis, M. et al. (2017) Gut Symbiont *Bacteroides fragilis* Secretes a Eukaryotic-Like
786 Ubiquitin Protein That Mediates Intraspecies Antagonism. MBio 8 (6).
- 787 115. Collier, R.J. and Cole, H.A. (1969) Diphtheria toxin subunit active in vitro. Science 164 (3884),
788 1179-81.